Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCA033989

Monoclonal antibody · Inhibitor of mutant calreticulin (mutCALR) (CALR) · developed by Incyte

Phase 3 Most advanced trial
INCY Developer
1 Registered trials

What is INCA033989?

INCA033989 is a human IgG1 monoclonal antibody that binds the mutated form of calreticulin (mutCALR) on CALR-mutated CD34-positive hematopoietic stem cells, sparing wild-type calreticulin. By blocking mutCALR complex formation with the thrombopoietin receptor, it suppresses TPO-R signaling and JAK2/STAT activation. It is being studied in essential thrombocythemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
mutant calreticulin (mutCALR) (CALR), thrombopoietin receptor (TPO-R) (MPL) (binding partner it blocks)
Mechanism
Inhibitor of mutant calreticulin (mutCALR) (CALR)
Pathways
JAK2/STAT signaling, TPO-R dimerization
Therapy area
Hematology, Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07623200 Phase 3 Essential Thrombocythemia Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Essential Thrombocythemia

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCA033989

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.